LumiThera
Attila Kaplanci has a diverse work experience in the ophthalmology and medical field. Attila started their career as a Sales Area Manager at HEINE Optotechnik in 1997. Attila then went on to work as the Manager of International Sales at WISAP Medical from 2002 to 2003. In 2003, they joined Alcon as a Sales Manager Ophthalmology and later held positions such as Regional Refractive Manager and Business Development Manager in various regions. Attila joined Bausch + Lomb in 2018 as a Regional Sales Manager and later became the Managing Director Turkey - Vice President - Refractive at Medicals International. In 2019, they worked as the Director - Refractive Business at Vision Ophthalmology Group. In 2020, they became the Sales Director Europe at LumiThera, Inc. and currently holds the position of Senior Director of Sales EMEA.
Attila Kaplanci attended the University of Regensburg and Regensburger foreign languages school. Further details regarding the degree or field of study are not provided.
This person is not in any offices
LumiThera
1 followers
At LumiThera, they are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. They will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area.